Invasive mucinous adenocarcinoma of the lung (IMA), a mucinous variant of lung adenocarcinoma, is strongly linked with a worse prognosis. Therefore, a deeper understanding about its molecular mechanism may conduce to a promising IMA therapy. Long non-coding RNAs (lncRNAs) have recently caught great attention for their crucial roles in diverse diseases regarding tumor initiation and progression. However, the potential role of the lncRNA HOXC-AS3 IMA is not well established. Hence, the purpose of present study is to manifest HOXC-AS3-regulated inner mechanism in IMA development. It revealed that HOXC-AS3 was highly expressed in IMA cells. Additionally, it was identified that the significant down-regulation of HOXC-AS3 obstructed cell proliferation and migration in IMA. As far as mechanism is concerned, it found that HOXC-AS3 recruited FUS to stabilize FOXM1 mRNA, accelerating IMA progression. Taken together, these data suggested that HOXC-AS3 may be recognized as a novel therapeutic target for patients with IMA or at least offer new views for molecular therapy.

中文翻译：

---

较长的非编码RNA HOXC-AS3通过调节FUS / FOXM1促进肺部浸润性黏液性腺癌的发展。

肺部浸润性黏液性腺癌（IMA）是肺部腺癌的黏液性变体，与不良预后密切相关。因此，对其分子机制的更深入的了解可能有助于有希望的IMA治疗。长的非编码RNA（lncRNA）最近因在各种疾病中与肿瘤的发生和发展有关的关键作用而备受关注。但是，lncRNA HOXC-AS3 IMA的潜在作用尚不明确。因此，本研究的目的是在IMA发展中表现出HOXC-AS3调节的内部机制。这表明HOXC-AS3在IMA细胞中高度表达。此外，已确定HOXC-AS3的显着下调阻碍了IMA中的细胞增殖和迁移。就机制而言，它发现HOXC-AS3募集了FUS来稳定FOXM1 mRNA，加速IMA进程。综上，这些数据表明，HOXC-AS3可能被认为是IMA患者的新型治疗靶标，或者至少为分子治疗提供了新的见解。